生命科学资讯

Senate hearing raises FDA-related concerns for new rare disease drugs

Viatris plans to lay off up to 10% of staff, discloses Indian factory fire

Why did my doctor push Grail’s dubious cancer test?

AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug

Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

Salma Health raises $80M for its clinics to treat brain health

OrbiMed jumps to number one on the top 100 list of biotech venture investors

Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects

Japan's Asahi Kasei to buy German biotech Aicuris for $920M

Sarepta CEO Doug Ingram to step down

Gilead, Merck plan to debut new daily HIV pills

Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug

Charles River sells its CDMO and European discovery businesses

Accent axes a cancer study; Werewolf considers its options

Alkermes CEO Richard Pops to retire after 35-year tenure